Request Demo
Last update 09 Jun 2025
BMS-986263
Last update 09 Jun 2025
Overview
Basic Info
Drug Type siRNA |
Synonyms BMS 986263, ND-L02-S0201 |
Target |
Action inhibitors |
Mechanism SERPINH1 gene inhibitors |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization |
Drug Highest PhaseDiscontinuedPhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Structure/Sequence
Boost your research with our RNA technology data.
login
or
Related
9
Clinical Trials associated with BMS-986263NCT04267393
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multiple-Dose Phase 2 Study to Evaluate the Efficacy and Safety of BMS-986263 in Adults With Compensated Cirrhosis From Nonalcoholic Steatohepatitis (NASH)
NCT04225936
An Open-label, Two-Part, Single-dose Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-986263 in Participants With Varying Degrees of Hepatic Impairment
NCT03538301
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Biological Activity, and PK of ND-L02-s0201 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
100 Clinical Results associated with BMS-986263
Login to view more data
100 Translational Medicine associated with BMS-986263
Login to view more data
100 Patents (Medical) associated with BMS-986263
Login to view more data
4
Literatures (Medical) associated with BMS-98626301 Oct 2023Clinical and translational science
Pharmacokinetics, safety, and tolerability of BMS-986263, a lipid nanoparticle containing HSP47 siRNA, in participants with hepatic impairment.
Article
Author: Charles, Edgar D ; de Oliveira, Claudia H M C ; Lawitz, Eric J ; Wetherington, Jeffrey ; Qosa, Hisham ; Cizza, Giovanni ; Colletti, Nicholas ; Tirucherai, Giridhar S
BMS-986263 is a retinoid-conjugated lipid nanoparticle delivering small interfering RNA designed to inhibit synthesis of HSP47 protein, a collagen-specific chaperone protein involved in fibrosis development. This is a phase I, open-label, two-part study evaluating pharmacokinetics and safety of BMS-986263 in participants with hepatic impairment (HI). Part 1 (n = 24) of this study enrolled two cohorts with mild and moderate HI and a separate cohort of age- and body mass index (BMI)-matched participants with normal hepatic function. Part 2 enrolled eight participants with severe HI and eight age- and BMI-matched participants with normal hepatic function. All participants received a single intravenous 90 mg BMS-986263 infusion. Compared with normal-matched participants, geometric mean area under the plasma concentration-time curve time zero to the time of the last quantifiable concentration (AUC(0-T) ) and AUC from zero to infinity (AUC(INF) ) of HSP47 siRNA were similar in participants with mild HI and 34% and 163% greater in those with moderate and severe HI, respectively, whereas the maximum plasma concentration was ~25% lower in mild and moderate HI groups but 58% higher in the severe HI group than in the normal group. Adverse events were reported by two of eight, four of eight, and three of eight participants with mild, moderate, or severe HI, respectively; none were reported in the normal-matched group. Overall, single-dose BMS-986263 was generally safe and well-tolerated and dose adjustment is not considered necessary for participants with mild or moderate HI. Although available data do not indicate that dose adjustment should be performed in patients with severe HI; the optimal posology of BMS-986263 in patients with severe HI may be determined later in its clinical development when additional data to establish exposure-safety/efficacy relationship becomes available.
01 Apr 2022Hepatology (Baltimore, Md.)Q1 · MEDICINE
BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial
Q1 · MEDICINE
Article
Author: Kavita, Uma ; Shevell, Diane E. ; Coste, Angie ; Chen, Warner ; Karsdal, Morten ; Nielsen, Mette ; Du, Shuyan ; Poordad, Fred ; Tirucherai, Giridhar S. ; Charles, Edgar D. ; Goodman, Zachary ; Lawitz, Eric J.
Abstract:
Background and Aims:
Hepatic fibrosis secondary to HCV infection can lead to cirrhosis and hepatic decompensation. Sustained virologic response (SVR) is possible with direct‐acting antiviral drug regimens; however, patients with advanced fibrosis have an increased risk for HCC. Heat shock protein 47 (HSP47), a key collagen chaperone, has been implicated in fibrosis development. We evaluated the efficacy and safety of BMS‐986263, a lipid nanoparticle delivering small interfering RNA designed to degrade HSP47 mRNA, for the treatment of advanced fibrosis.
Approach and Results:
NCT03420768 was a Phase 2, randomized (1:1:2), placebo‐controlled trial conducted at a hepatology clinic in the United States. Patients with HCV‐SVR (for ≥ 1 year) and advanced fibrosis received once‐weekly i.v. infusions of placebo or BMS‐986263 (45 or 90 mg) for 12 weeks. The primary endpoint was ≥ 1 METAVIR stage improvement at Week 12; key secondary endpoints included Ishak score improvement, pharmacokinetics, fibrosis biomarkers, and safety. All 61 patients completed treatment, and 2/15 (13%, placebo), 3/18 (17%, 45 mg), and 6/28 (21%, 90 mg) had METAVIR improvements of ≥ 1 stage at Week 12. Five patients in the 90‐mg arm had Ishak improvements by ≥ 2 stages. BMS‐986263 plasma concentrations increased in a generally dose‐proportional fashion between BMS‐986263 doses, with no notable accumulation with weekly dosing. All adverse events (AEs) were mild or moderate in intensity; most treatment‐related AEs were infusion‐related reactions in the BMS‐986263 arms. At baseline, collagen levels were low, indicating low levels of fibrogenesis in these patients.
Conclusions:
In patients with HCV‐SVR, BMS‐986263 administration was generally well tolerated through Week 36 and resulted in METAVIR and Ishak score improvements. Further evaluation of BMS‐986263 in patients with active fibrogenesis is warranted.
01 Apr 2021ERJ open research
Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models
Article
Author: Quimbo, Alistair ; Zabludoff, Sonya ; Ying, Wenbin ; Clamme, Jean-Pierre ; Liu, Jian ; Yao, Jiping ; Liu, Yun ; Zhang, Jun ; Xia, Fengcheng
ND-L02-s0201 is a lipid nanoparticle encapsulating an siRNA which inhibits expression of heat shock protein 47 (HSP47), a collagen-specific chaperone. Accumulated evidence demonstrates a close association between increased level of HSP47 and excessive accumulation of collagen in fibrotic diseases. Our objective was to test ND-L02-s0201 efficacy in preclinical lung fibrosis models and characterise the downstream histological and functional consequences of inhibiting the expression of HSP47.Comprehensive optimisation and characterisation of bleomycin (BLM) and silica-induced rat lung fibrosis models were conducted, which ensured progressive pathological changes were sustained throughout the study during evaluation of the anti-fibrotic potential of ND-L02-s0201.In the BLM model, we demonstrated dose-dependent and statistically significant reduction in the relative lung weight, collagen deposition and histology, and fibrosis scores following ND-L02-s0201 treatment. Lung tissue mRNA profiling demonstrated that 11 out of 84 fibrosis-relevant genes were upregulated following BLM induction and were downregulated by approximately 4.5-fold following ND-L02-s0201 treatment. Epithelial–mesenchymal transition was characterised in the BLM model following ND-L02-s0201 treatment. Cell enrichment demonstrated that myofibroblasts contained the highest HSP47 mRNA expression. BLM led to more than a five-fold increase in myofibroblasts and ND-L02-s0201 treatment reduced the myofibroblasts to sham levels. Statistically significant improvement in lung function was noted in the BLM model which was determined by running endurance capacity using a 7-minute treadmill test. Comparable anti-fibrotic efficacy was also observed in the silica model.Results from two robust chronic rodent models of pulmonary fibrosis demonstrated significant anti-fibrotic effects and improved lung function which support the evaluation of ND-L02-s0201 in subjects with idiopathic pulmonary fibrosis.
5
News (Medical) associated with BMS-98626303 Jan 2024
AcquisitionPhase 2
14 Sep 2023
Phase 1Phase 2PROTACsClinical Trial TerminationLicense out/in
25 May 2023
100 Deals associated with BMS-986263
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Nonalcoholic Steatohepatitis | Phase 2 | United States | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Japan | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Argentina | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Belgium | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Brazil | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Canada | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | France | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Germany | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Israel | 17 Mar 2021 | |
| Nonalcoholic Steatohepatitis | Phase 2 | Italy | 17 Mar 2021 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 124 | Placebo | cemdjnjbml = lkhgnnnvci vhgyzatqpg (dlqbaysiax, iowfvdzxro - qfzenwkcld) View more | - | 04 Sep 2024 | ||
Phase 2 | 123 | Other: Placebo | parwslvtzv = buedjsebqx kfwqjtdirv (ttcmzgayia, rjvyaynpyg - tnpmlxjxoj) View more | - | 11 Dec 2023 | ||
Phase 1 | 8 | brclyvblbv(ndjekmmbue) = 1 in BMS-986263, 0 in normal-matched snzjbjkmuo (zlzkzmvjwj ) View more | Positive | 25 Jun 2022 | |||
Phase 2 | 61 | (BMS-986263 45 mg QW (Once Weekly)) | ikiyfszved = gtiwfnltpx lsdeylmwdq (tysuvkbgzv, jhxaplfxvf - wnglbvhgcu) View more | - | 04 Feb 2022 | ||
(BMS-986263 90 mg QW (Once Weekly)) | ikiyfszved = scxzfoatjt lsdeylmwdq (tysuvkbgzv, vdagijbiks - daejskmfuy) View more | ||||||
NCT03420768 (Pubmed) Manual  | Phase 2 | 61 | lsxpqxjcmm(wcgtcewaje) = qjxorgfzxk uotowejjms (cttkfujeiw ) View more | Positive | 04 Oct 2021 | ||
Placebo | lsxpqxjcmm(wcgtcewaje) = jiiefxqron uotowejjms (cttkfujeiw ) |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free